Latest news and press releases about Korro Bio, Inc. (KRRO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Price
| Price | $13.83 |
| Market Cap | $138M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.41 |
| EV / EBITDA | -1.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -114.26% |
| Return on Invested Capital | -49.21% |
| Return on Assets | -65.25% |
| Gross Margin | 72.75% |
| Operating Margin | -3176.57% |
| Net Margin | -4477.08% |
Related companies: ALT · AMRN · ANNX · ANRO · AURA · DBVT · ENGN
Explore sector: Healthcare · Biotechnology
More sections of KRRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks